Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. - Wikidata - awgldk - TriplyDB

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

http://www.wikidata.org/entity/Q34431275

about

Optimizing the initial choice and timing of therapy in relapsing-remitting multiple sclerosis Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?Pharmacological Approaches to Delaying Disability Progression in Patients with Multiple Sclerosis Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis The Diagnosis and Treatment of Optic Neuritis Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE Current perspectives on interferon Beta-1b for the treatment of multiple sclerosis Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).The 11-year long-term follow-up study from the randomized BENEFIT CIS trial.Time course of glatiramer acetate efficacy in patients with RRMS in the GALA study.Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.Effectiveness of multiple sclerosis treatment with current immunomodulatory drugs.Pharmacokinetics and pharmacodynamics of MD1003 (high-dose biotin) in the treatment of progressive multiple sclerosis.Optimization and stratification of multiple sclerosis treatment in fast developing economic countries: a perspective from Qatar.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Future placebo-controlled trials of disease modifying therapy in relapsing multiple sclerosis would be unethical: Commentary.Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.Optic neuritis: Observation and experience at a tertiary care hospital in Qassim region, Saudi Arabia.Clinically Isolated Syndrome According to McDonald 2010: Intrathecal IgG Synthesis Still Predictive for Conversion to Multiple Sclerosis.Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy-NO.["Time is brain" in relapsing remitting multiple sclerosis. Current treatment concepts in immunotherapy].Prevalence and factors leading to unemployment in MS (multiple sclerosis) patients undergoing immunomodulatory treatment in Poland.

P2860

Q26777686-9B56AAF6-CFF0-428E-BE71-C77E145A7EC8 Q26798434-DD14F179-9D91-4CA4-84A1-F1A914C521A6 Q27000269-1FAD795B-7FEB-4DBC-B06E-5356EEA559F2 Q30234672-7B2FA79C-9ABE-4177-B600-D55DBA39616A Q30278095-C1ECCD49-E103-4850-8215-EB0A0D96C965 Q30995944-16A1135B-F87C-4A2D-B165-9693151AAD2C Q33589940-563050D4-ECC2-408B-AE68-DA22041C1FFD Q34253488-FE448D34-56EB-419B-9579-E6A991D10416 Q36389706-5AFCB0CF-B170-41DE-8497-051AFAF3BCBE Q37265162-1D80C720-F51B-4FF3-8436-63B93CCFC57E Q37633582-194F9A67-7211-4EE6-83B2-FA18A753CFA4 Q38265170-19901975-6B1F-4C3C-9B53-10107D310C27 Q38315992-FAF0ECB9-D35F-4201-8F65-664E73BB89B2 Q38677868-8DCC6598-7E69-4D0D-AE2C-2B70BB79B1D3 Q39021942-57737611-C404-474E-B452-5FBEDE4338BE Q39027028-E08F30E1-0EE8-4CE4-9C2D-3C758D7FB501 Q39151223-39FC37B9-31FE-4BD1-B19D-AA3E4414E740 Q41681605-4B28AF8E-8FDD-4755-A31C-E2FCE27B843A Q46424608-C2925D39-AC3B-472C-945A-CC18E2415DDF Q47105069-5DFDDC4F-6D10-48F4-B252-1DD4E422853E Q47719573-C1C1994A-2884-4B46-B0FD-97AEB52768ED Q50800618-211E12FC-A646-451F-BD51-9402828C461F Q53288359-C3B9FE62-9E6A-480D-BA7C-B6046939EBCF Q55396508-8A88217C-DE68-4E4E-88CC-A58535E93E13

P2860

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

http://www.wikidata.org/entity/Q34431275

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@ast

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@en

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@nl

type

label

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@ast

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@en

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@nl

prefLabel

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@ast

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@en

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.

@nl

P1433

Q34431275-BE843391-C553-498E-9C52-88D44C6642E8

P1476

Q34431275-0CF7D945-98D9-49D1-B16E-43AD36F00373

P2093

Q34431275-2D2CE6C3-BF33-449E-B3DD-8F1A51730E0A

Q34431275-3C6E8992-2736-4630-AC8E-418D299F668D

Q34431275-59AF5884-27F0-4A12-BC79-850675E58374

Q34431275-66E313D7-3638-401E-823D-C0823784E77A

Q34431275-6BBFADAA-4166-4E7B-B839-D3247CBE523D

Q34431275-7C0B6FB6-C378-4C6B-A104-41FA27AA5AEB

Q34431275-7D7C1D52-8B0C-49DD-9F8F-C27F0BEEB2F4

Q34431275-A916BC71-5819-4DE6-A159-A2A8D28EF534

Q34431275-B4ADA5B1-7058-4949-BD20-394820AD64EC

Q34431275-BA46EAC7-19DE-4D76-8733-86FD02B61FEB

P2860

Q34431275-0A284820-B706-4322-AB76-B90C39932E43

Q34431275-2CD82B87-48DB-4751-BC22-51B7A7ECE764

Q34431275-3A9607B1-6FFB-4A27-833B-A7A7EF7A6199

Q34431275-41576EB0-36DA-4CBA-8D5A-868ED5953090

Q34431275-46193908-8D3A-453C-8F81-6B17767E4B11

Q34431275-468E9FD5-2F7C-4C84-8331-88F5155F5915

Q34431275-50A76E23-FF95-481A-9223-FB1AE484A347

Q34431275-94A16062-7F67-4C6C-9C19-96A4E0E82036

Q34431275-999A1911-7798-49D3-B10E-7406CB42142B

Q34431275-A1D0A295-FC5E-4A66-A275-9D325E5C2B70

P304

Q34431275-157A0ED0-11D9-424E-B11D-1078FD55979E

P31

Q34431275-F09855E2-EBB5-4ABB-8F13-7EF9BE57AD04

P356

Q34431275-C92E026E-4DAC-466A-AFE6-EF40AA299988

P407

Q34431275-FC597E66-8D3D-4085-B134-98C6A7B87CBE

P433

Q34431275-2BAF94C0-6001-495C-879F-D98B49B4B029

P478

Q34431275-D52D6569-428E-4CF3-A295-9D7C2A540F1E

P50

Q34431275-05027219-A2E9-48FA-B26F-A8DBCA3D600A

P577

Q34431275-DB246FBF-2D1C-44E1-A846-786414772444

P5875

Q34431275-542B0A67-C2F2-4135-A47E-6D19F64D8645

P698

Q34431275-137C34AB-2940-4F83-A03D-6E8A60D5B5DF

P932

Q34431275-0329A60B-AA0E-4695-979A-A28DC12C127C

P356

JNNP-2013-306222

P1433

Journal of Neurology, Neurosurgery and Psychiatry

P1476

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

@en

P2093

B Stemper

http://www.w3.org/2001/XMLSchema#string

BENEFIT Study Group

http://www.w3.org/2001/XMLSchema#string

C H Polman

http://www.w3.org/2001/XMLSchema#string

C Pohl

http://www.w3.org/2001/XMLSchema#string

D Miller

http://www.w3.org/2001/XMLSchema#string

D Pleimes

http://www.w3.org/2001/XMLSchema#string

F Barkhof

http://www.w3.org/2001/XMLSchema#string

G Edan

http://www.w3.org/2001/XMLSchema#string

H-P Hartung

http://www.w3.org/2001/XMLSchema#string

J Herrmann

http://www.w3.org/2001/XMLSchema#string

P2860

EuroQol--a new facility for the measurement of health-related quality of life

Multiple sclerosis

Evidence for a two-stage disability progression in multiple sclerosis

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability

New diagnostic criteria for multiple sclerosis: guidelines for research protocols.

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.

Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.

Development of a multiple sclerosis functional composite as a clinical trial outcome measure.

P304

1183-1189

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/JNNP-2013-306222

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

85

http://www.w3.org/2001/XMLSchema#string

P50

Xavier Montalban

P577

2013-11-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262044864

http://www.w3.org/2001/XMLSchema#string

P698

24218527

http://www.w3.org/2001/XMLSchema#string

P932

4215285

http://www.w3.org/2001/XMLSchema#string